John T. Kemshead – författare

This monograph explains the considerable impact that monoclonal antibodies and molecular probes have had on the diagnosis of tumor types and sub-types. It explains how radiolabelled monoclonal antibodies have also been used as imaging agents to try to improve the oncologist's ability to define residual tumor deposits after combination chemo/radiotherapy. Finally, the childhood malignancies that still have a poor prognosis are presented, and new novel ways of therapy are explained.

This monograph explains the considerable impact that monoclonal antibodies and molecular probes have had on the diagnosis of tumor types and sub-types. It explains how radiolabelled monoclonal antibodies have also been used as imaging agents to try to improve the oncologist's ability to define residual tumor deposits after combination chemo/radiotherapy. Finally, the childhood malignancies that still have a poor prognosis are presented, and new novel ways of therapy are explained.

This monograph explains the considerable impact that monoclonal antibodies and molecular probes have had on the diagnosis of tumor types and sub-types. It explains how radiolabelled monoclonal antibodies have also been used as imaging agents to try to improve the oncologist''s ability to define residual tumor deposits after combination chemo/radiotherapy. Finally, the childhood malignancies that still have a poor prognosis are presented, and new novel ways of therapy are explained.